News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,386 Results
Type
Article (42805)
Company Profile (282)
Press Release (672298)
Multimedia
Podcasts (71)
Webinars (14)
Section
Business (206190)
Career Advice (2116)
Deals (36893)
Drug Delivery (102)
Drug Development (81830)
Employer Resources (173)
FDA (16435)
Job Trends (15156)
News (350033)
Policy (33231)
Tag
Academia (2625)
Accelerated approval (9)
Adcomms (24)
Allergies (96)
Alliances (50255)
ALS (109)
Alzheimer's disease (1450)
Antibody-drug conjugate (ADC) (160)
Approvals (16428)
Artificial intelligence (342)
Autoimmune disease (32)
Automation (18)
Bankruptcy (371)
Best Places to Work (11791)
BIOSECURE Act (19)
Biosimilars (123)
Biotechnology (196)
Bladder cancer (95)
Brain cancer (37)
Breast cancer (366)
Cancer (2884)
Cardiovascular disease (214)
Career advice (1771)
Career pathing (32)
CAR-T (197)
CDC (32)
Cell therapy (519)
Cervical cancer (22)
Clinical research (67324)
Collaboration (1032)
Company closure (3)
Compensation (680)
Complete response letters (22)
COVID-19 (2664)
CRISPR (58)
C-suite (324)
Cystic fibrosis (114)
Data (2985)
Decentralized trials (2)
Denatured (20)
Depression (61)
Diabetes (352)
Diagnostics (6481)
Digital health (26)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (157)
Drug pricing (124)
Drug shortages (29)
Duchenne muscular dystrophy (125)
Earnings (87740)
Editorial (40)
Employer branding (21)
Employer resources (150)
Events (114473)
Executive appointments (853)
FDA (18100)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (940)
Gene editing (133)
Generative AI (27)
Gene therapy (380)
GLP-1 (809)
Government (4582)
Grass and pollen (4)
Guidances (181)
Healthcare (19075)
Huntington's disease (30)
IgA nephropathy (41)
Immunology and inflammation (153)
Immuno-oncology (8)
Indications (39)
Infectious disease (2839)
Inflammatory bowel disease (151)
Inflation Reduction Act (10)
Influenza (64)
Intellectual property (120)
Interviews (336)
IPO (16699)
IRA (47)
Job creations (3762)
Job search strategy (1495)
Kidney cancer (14)
Labor market (52)
Layoffs (522)
Leadership (20)
Legal (8142)
Liver cancer (80)
Lung cancer (405)
Lymphoma (209)
Machine learning (11)
Management (60)
Manufacturing (401)
MASH (92)
Medical device (13637)
Medtech (13642)
Mergers & acquisitions (20918)
Metabolic disorders (863)
Multiple sclerosis (98)
NASH (17)
Neurodegenerative disease (118)
Neuropsychiatric disorders (33)
Neuroscience (2138)
NextGen: Class of 2025 (6670)
Non-profit (4542)
Now hiring (47)
Obesity (434)
Opinion (235)
Ovarian cancer (101)
Pain (104)
Pancreatic cancer (120)
Parkinson's disease (189)
Partnered (22)
Patents (299)
Patient recruitment (161)
Peanut (51)
People (58245)
Pharmaceutical (71)
Pharmacy benefit managers (22)
Phase I (20978)
Phase II (29626)
Phase III (22094)
Pipeline (1630)
Policy (204)
Postmarket research (2598)
Preclinical (8946)
Press Release (66)
Prostate cancer (139)
Psychedelics (36)
Radiopharmaceuticals (261)
Rare diseases (466)
Real estate (6015)
Recruiting (66)
Regulatory (22991)
Reports (51)
Research institute (2378)
Resumes & cover letters (364)
Rett syndrome (9)
RNA editing (8)
RSV (50)
Schizophrenia (91)
Series A (160)
Series B (110)
Service/supplier (12)
Sickle cell disease (61)
Special edition (20)
Spinal muscular atrophy (150)
Sponsored (32)
Startups (3690)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (49)
Vaccines (794)
Venture capital (54)
Weight loss (267)
Women's health (45)
Worklife (16)
Date
Last 7 days (387)
Last 30 days (1844)
Last 365 days (31938)
2025 (17082)
2024 (35770)
2023 (40359)
2022 (51485)
2021 (56079)
2020 (54531)
2019 (47159)
2018 (35568)
2017 (32657)
2016 (32095)
2015 (38109)
2014 (31853)
2013 (26903)
2012 (29101)
2011 (29786)
2010 (27897)
Location
Africa (757)
Alabama (61)
Alaska (7)
Arizona (245)
Arkansas (13)
Asia (39266)
Australia (6396)
California (7434)
Canada (2355)
China (680)
Colorado (321)
Connecticut (319)
Delaware (192)
Europe (84639)
Florida (1120)
Georgia (248)
Hawaii (1)
Idaho (62)
Illinois (644)
India (26)
Indiana (362)
Iowa (16)
Japan (227)
Kansas (108)
Kentucky (30)
Louisiana (15)
Maine (64)
Maryland (1029)
Massachusetts (5555)
Michigan (247)
Minnesota (449)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (69)
New Jersey (2087)
New Mexico (29)
New York (2099)
North Carolina (1082)
North Dakota (8)
Northern California (3265)
Ohio (238)
Oklahoma (16)
Oregon (35)
Pennsylvania (1613)
Puerto Rico (17)
Rhode Island (36)
South America (1143)
South Carolina (34)
South Dakota (1)
Southern California (2772)
Tennessee (127)
Texas (1116)
United States (27634)
Utah (222)
Virginia (183)
Washington D.C. (74)
Washington State (634)
West Virginia (4)
Wisconsin (65)
715,386 Results for "myokardia inc acquired by bms".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Series A
MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make cardiovascular disease curable and preventable.
January 10, 2025
·
2 min read
·
Heather McKenzie
Layoffs
BMS Continues New Jersey Layoffs, Bringing Yearly Total to Nearly 900
BMS is letting go of 68 employees in Lawrenceville, New Jersey. The pharma has now cut over 1,000 employees there since April 2024 as part of its cost-cutting measures.
June 30, 2025
·
1 min read
·
Angela Gabriel
Deals
BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem
Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead collaborate on an early-stage molecule that binds to a novel marker called ACP3.
June 11, 2025
·
2 min read
·
Tristan Manalac
Legal
BMS, Sanofi Settle Plavix Suit With Hawaii for $700M
The Plavix lawsuit dates back to 2014, when Hawaii first sued BMS and Sanofi, alleging that they failed to properly inform patients in the state that the drug is likely to be less effective for them.
May 12, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
BMS Pledges $40B Investment in US Despite Cost-Cutting Plans
In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing investments in the U.S., including Eli Lilly, Johnson & Johnson and Novartis. BMS is the latest to make a multibillion-dollar push.
May 6, 2025
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia
Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos was unable to improve disease burden in non-obstructive hypertrophic cardiomyopathy.
April 23, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement
Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.
March 11, 2025
·
3 min read
·
Tristan Manalac
Cardiovascular disease
BMS’ Camzyos Fails To Show New Cardiomyopathy Benefit in Phase III
According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion label expansion opportunity for Camzyos.
April 15, 2025
·
2 min read
·
Tristan Manalac
FDA
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.
January 2, 2025
·
2 min read
·
Kate Goodwin
Cancer
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
February 14, 2025
·
2 min read
·
Tristan Manalac
1 of 71,539
Next
